%0期刊文章%A Olayanju, Olatunde %A Esmail, Aliasgar %A Limberis, Jason %A Dheda，Keertan % T包含bedaquiline方案和delamanid bedaquiline相比,耐药结核病患者2020% % D R 10.1183/13993003.01181 J欧洲呼吸杂志-2019% % P 1901181 X % V 55% N 1%有有限的数据结合delamanid和bedaquiline耐药结核病(DR-TB)方案。目前还没有包括艾滋病毒感染者在内的预期长期结果数据。在2014年至2018年期间，我们对122名南非耐药结核病患者(52.5%艾滋病毒感染者)进行了前瞻性随访。我们对接受以贝达奎林为基础方案的患者(n=82)与接受贝达奎林-德拉曼胺联合方案的患者(n=40)的疗效和安全性进行了比较。6个月培养转化率无显著差异(92.5%对81.8%;P =0.26)和18个月的预后良好率(63.4%对67.5%;P =0.66)，尽管后者具有更严重的耐药性(3.7% vs 22.5%对至少5种药物耐药;p=0.001)和更高的治疗前失败率(治疗前耐多药结核病治疗失败为12.2%，治疗前耐多药结核病治疗失败为52.5%;p < 0.001)。尽管使用Fridericia公式修正的QT间期延长比例在联合组中较高(>比基线延长60 ms (p=0.001)或>治疗期间延长450 ms (p=0.001))，但两组均未出现症状或停药。 Results were similar in HIV-infected patients.A bedaquiline–delamanid combination regimen showed comparable long-term safety compared to a bedaquiline-based regimen in patients with DR-TB, irrespective of HIV status. These data inform regimen selection in patients with DR-TB from TB-endemic settings.A bedaquiline–delamanid combination regimen in drug-resistant tuberculosis patients with poor prognostic factors showed comparable efficacy and safety to those in a bedaquiline-based regimen http://bit.ly/32j7Fyo %U //www.qdcxjkg.com/content/erj/55/1/1901181.full.pdf